Sutro Biopharma, Inc. (STRO)

STRO Investigation 

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sutro Biopharma, Inc. ("Sutro" or "the Company") (NASDAQ: STRO). The investigation concerns whether Sutro and certain of its officers and/or directors have violated federal securities laws.


In September 2018, Sutro conducted its initial public offering, selling 5,667,000 shares of common stock priced at $15.00 per share.  On May 11, 2020, post-market, Sutro issued a press release reporting its financial and operating results for the first quarter of 2020.  For the quarter, Sutro reported a net loss per share of $0.84 on revenues of $7.15 million, both of which metrics fell significantly short of consensus estimates.  On this news, Sutro’s stock price fell sharply during intraday trading on May 12, 2020.


If you are aware of any facts relating to this investigation, or purchased Sutro shares, you can also contact Peretz Bronstein of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2020 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon
  • LinkedIn

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.